COMMUNIQUÉS West-GlobeNewswire

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

09/08/2024 - 22:40

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead [...]

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:30

CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

09/08/2024 - 22:30

Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase [...]

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

09/08/2024 - 22:20

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

09/08/2024 - 22:15

HUNTSVILLE, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, today [...]

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

09/08/2024 - 22:05

- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024 [...]

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:05

BRISBANE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on August 6, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock [...]

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:05

MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

09/08/2024 - 22:05

JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial [...]

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

09/08/2024 - 22:05

– 2 nd quarter conference call to be held Tuesday, August 13 th , at 8:30 a.m. ET – DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company [...]

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/08/2024 - 22:05

SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

09/08/2024 - 22:04

Study validates siRNA produced by new GMP-compliant Manufacturer and Company’s Exosomes for Drug Delivery TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) ( [...]

Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering

09/08/2024 - 21:38

DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced a [...]

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

09/08/2024 - 21:21

TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S [...]

Sanofi: Information concerning the total number of voting rights and shares - July 2024

09/08/2024 - 21:11

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2024

09/08/2024 - 21:11

Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

09/08/2024 - 20:29

Bagsværd, Denmark, 9 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]

OneMedNet Revolutionizes Data Curation with AI, Boosting Efficiency up to 5X

09/08/2024 - 19:40

MINNEAPOLIS, Aug. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (RWD), has successfully integrated its [...]

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

09/08/2024 - 18:49

neffy Offers Adults and Children (≥30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years Well-capitalized to Support Launch and Commercialization of neffy in [...]